UK Markets closed

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.25-0.21 (-3.85%)
At close: 4:00PM EDT

CytomX Therapeutics, Inc.

151 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
650 515 3185
http://www.cytomx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees144

Key executives

NameTitlePayExercisedYear born
Dr. Sean A. McCarthyChairman, CEO & Pres957k1.16M1967
Mr. Frederick W. GluckCo-Founder & Independent Director50.5kN/A1935
Mr. Carlos CampoySr. VP & CFO768.78kN/A1965
Mr. Lloyd A. Rowland Jr., J.D.Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec.574.82kN/A1957
Dr. Amy C. Peterson M.D.Exec. VP & Chief Devel. Officer804.8kN/A1967
Dr. Alison L. HannahSr. VP & Chief Medical Officer654.56kN/A1961
Dr. Chau Cheng M.B.A., Ph.D.VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Danielle OlanderSr. VP, Talent & Systems Devel.N/AN/AN/A
Ms. Alison JolySr. VP of Program & Alliance ManagementN/AN/AN/A
Ms. Leslie RobbinsSr. VP of Intellectual PropertyN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Corporate governance

CytomX Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2021 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.